PNC-27 Peptide: A Potent Anti-Cancer Agent Targeting Leukemia Cells
Discover the groundbreaking potential of PNC-27, a peptide designed for selective cancer cell targeting. This advanced therapeutic agent, manufactured in China, offers a novel approach to treating leukemia by inducing necrosis through a unique interaction with membrane-bound HDM-2 protein, while exhibiting minimal toxicity to normal cells.
Get a Quote & SampleTargeted Cancer Therapy with PNC-27
PNC-27 Peptide
As a leading manufacturer and supplier, we offer high-purity PNC-27 peptide. This innovative anticancer agent is formulated as a white powder and has demonstrated significant selective cytotoxicity against various leukemia cell lines, including U937, OCI-AML3, and HL60. Our commitment to quality ensures reliable supply for your research and development needs.
- Selective Cytotoxicity: PNC-27 targets cancer cells by interacting with membrane-bound HDM-2, inducing necrosis without harming normal cells, making it a valuable agent for targeted cancer therapies.
- Mechanism of Action: The peptide forms transmembrane pores, leading to cell lysis and death, a process that is independent of p53 status.
- Leukemia Treatment Potential: Clinical and preclinical studies show potent anti-leukemic activity, with low IC50 values observed in various leukemia cell lines.
- Supplier Assurance: We are a trusted supplier, ensuring the consistent quality and availability of PNC-27 for your demanding applications. Purchase high-quality PNC-27 from us.
Key Advantages of PNC-27
Selective Tumor Targeting
PNC-27's unique interaction with membrane-bound HDM-2 ensures that its cytotoxic effects are primarily directed towards cancer cells, minimizing off-target toxicity and enhancing therapeutic specificity. This makes it an attractive component for advanced cancer drug development.
Necrosis Induction Mechanism
Unlike apoptosis, PNC-27 induces cell death through necrosis by forming transmembrane pores. This distinct mechanism of action is crucial for overcoming treatment resistance in certain cancer types and is a key focus for researchers seeking novel anticancer agents.
P53-Independent Efficacy
The anticancer activity of PNC-27 is independent of the p53 tumor suppressor gene status. This is particularly important as p53 mutations are common in many cancers, including leukemia, allowing PNC-27 to be effective even in p53-mutated or null cancers.
Applications and Research Areas
Leukemia Therapy
PNC-27 demonstrates significant potential in treating various forms of leukemia, including AML, by selectively killing malignant cells while sparing normal hematopoietic cells. Its efficacy against stem-cell enriched populations makes it a compelling candidate for further clinical investigation.
Oncology Drug Development
As a promising peptide therapeutic, PNC-27 serves as a valuable tool for researchers in oncology drug development. Its unique mechanism provides a basis for exploring novel targeted cancer therapies and combination treatments.
Molecular Oncology Research
Investigating the interaction between PNC-27 and membrane-bound HDM-2 offers insights into cancer cell biology and targeted therapy design. Understanding these molecular mechanisms is key to developing next-generation anticancer agents.
Custom Peptide Synthesis Services
For researchers requiring specific formulations or quantities, we offer custom peptide synthesis services for PNC-27, ensuring that your project requirements are met with high-quality, precisely manufactured products.